Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04687358 · ClinicalTrials.gov registry record
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
A clinical trial of Recurrent Pericarditis, sponsored by Kiniksa Pharmaceuticals International.
- Active
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT04687358: Active study of Recurrent Pericarditis, sponsored by Kiniksa Pharmaceuticals International.
NCT04687358 is a study of Recurrent Pericarditis that is active but no longer recruiting, run by Kiniksa Pharmaceuticals International. The registered enrollment target is 500 participants, above the 101-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (395% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04687358, a study of Recurrent Pericarditis, is active but no longer recruiting, sponsored by Kiniksa Pharmaceuticals International.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Primary Outcome
Proportion of patients using 1, 2, 3, or more concomitant RP treatments
Conditions Studied
Study Locations (20)
California
- University of California San Diego Medical Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- Scripps Health - San Diego
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
- Mayo Clinic - PPDS - Rochester
New York
- NYU Langone Health - New York
- Northwell Health - Lenox Hill Hospital - New York
Ohio
- The Linder Research Center at The Christ Hospital - Cincinnati
- Cleveland Clinic - Cleveland
Alaska
- Alaska Heart & Vascular Institute - Anchorage
Arizona
- Pima Heart and Vascular - Tucson
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2029-03 |
What the registry record for NCT04687358 still lists
NCT04687358 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (395% higher).
The record links to 1 condition, with Recurrent Pericarditis appearing as the primary indexed condition, and to 0 interventions.
NCT04687358 names 20 study sites across 14 states, led by California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04687358 about?
NCT04687358 is a clinical study titled "REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients". The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations f...
What is the current status of trial NCT04687358?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2021-03-16. Estimated completion is 2029-03.
What conditions does trial NCT04687358 study?
This clinical trial studies the following conditions: Recurrent Pericarditis.
Who is sponsoring clinical trial NCT04687358?
This trial is sponsored by Kiniksa Pharmaceuticals International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04687358 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Pericarditis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transition to KPL-387 Monotherapy Dosing & Administration Study
RECRUITING · Phase 2
-
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
RECRUITING · Phase 2
-
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
RECRUITING · Phase 3
-
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI